JONT Journal

In OVQUEST trial [3], including 1360 cancer survivors, of which 421 (31%) OC survi-vors, 78% had chemotherapy induced peripheral neuropathy (CIPN), 60% suffered from persistent fatigue, 48% psychological issues and 59% sleep disorders. VIVROVAIRE I [4] demonstrated that, compared with healthy women, OC survivors had similar QoL but re-ported long-term fatigue, CIPN, distress and depression, and insomnia. Long-term fatigue was associated with depression, neuropathy, and sleep disorders. For EC patients, POR-TEC-3 [5] was a phase III trial in high risk EC comparing adjuvant chemoradiation fol-lowed by chemotherapy versus radiotherapy only. Long-term toxicity PORTEC-3 analysis demonstrated that chemoradiation was associated with more toxicity, such as CIPN, and deteriorated QoL [6]. The negative impact for the patients treated with chemoradiation was observed until 3 years with a physical and role functioning impairments.

The negative impact on QoL of the multimodal treatments in OC and EC is long last-ing. Zanderberg [7] reported the evolution of QoL among gynecological cancer survivors two years after the end of initial management: patients with comorbidities, with an advanced disease or treated with chemotherapy, had more physical functioning impairment during treatment and persistent cognitive and social functioning impairment after 12 months. Treatments sides effects appeared early with 50% of complications beginning during the first year after treatment. Nontheless, 10% of treatments sequelae appeared af-ter 60 months of follow-up, altering quality of life in emotional and physical domains of EC survivors.

Beyond these general side effects, OC and EC cancer survivors suffer from specific symptoms and sequelae directly related with gynecological cancer and treatments.

Fatigue, Sleep Disturbance and Psychological Disorders

Long-term fatigue is the most common issue among cancer survivors. Patients treat-ed for gynecological cancer experienced fatigue for 50% of them after surgery, 44% at 6 months and 39% at 12 months [8]. Long-term fatigue at 12 months, was associated with depression, or multiple comorbidities. In a cohort of 134 EC survivors, Xu et al [9], also de-scribed that altered sleep, comorbidities and younger age were risk factors for long-term fatigue.

Sleep disorders, such as insomnia, are frequent among OC and EC survivors during, and after their treatment. Sleep difficulties have a negative impact on QoL in this popula-tion of cancer survivors. In a study describing insomnia and sleep disorders in ovarian cancer [10], insomnia was associated with psychological issues (ie distress, depression) and altered QoL. Taking these difficulties into account, an interventional trial (NCT05044975) is ongoing to optimize a behavioral sleep intervention in order to diminish sleep disturbance among gynecologic cancer survivors [11].

The proportion of patients suffering from distress after OC and EC treatment is high [12]. In a cohort of 92 survivors who were at a median time of 7.6 months from primary treatment, 57% reported distress such as fatigue and worry. Distress was mainly observed for patients who had a high number of problems, or had unmet needs for rehabilitation services.

Anxiety and depression are the most prevalent psychological disorders, and are more frequent among cancer survivors than in the general population. Women treated for EC or OC are at higher risk for depression compared with healthy women [13]. The risk for de-pression symptoms is increased during primary care and remains increased for years af-ter diagnosis, despite oncologic care. Pharmacological solutions, such as antidepressant use, are preferentially observed for patients with comorbidities, advanced disease, or short education. Management of depression symptoms can rely on physical activity which had the ability to lower depressive symptoms in cancer survivors, but studies specifically con-cerning gynecological cancer survivors are lacking. Depression is particularly an issue among elderly women treated for OC or EC, and is more frequently reported for patients with comorbidities or functional limitations [14].

Genito-Urinary and Bowel Disorders

EC survivors are at higher risk for many genitourinary outcomes compared to wom-en from the general population: a cohort of 2648 EC survivors showed that, between 1 and 5 years after cancer diagnosis, those with higher stage, higher grade, older age and treated with radiation or chemotherapy were at higher risk for urinary disorders [15]. In another retrospective cohort of 149 EC survivors [16], 51% of women reported urine leakage. Significant risk factors for urinary incontinence were age (OR 1.06 95% CI 1.02, 1.10) and body mass index (BMI) (OR 1.07 95% CI 1.02, 1.11).

Bowel symptoms are also frequent. In a study including 623 gynecological cancer survivors (including EC and OC) and 344 population-based controls, Steineck et al. [17] found 30% urgency, 26% leakage syndrome, 15% excessive gas discharge, 16% excessive mucus discharge and 10% blood discharge after pelvic radiation. External beam pelvic radiation is responsible for longterm disorders as demonstrated in PORTEC-2 long term analysis. PORTEC-2 [18] is a phase III trial in EC comparing adjuvant vaginal brachy-therapy to standard pelvic radiation. In PORTEC-2 long-term analysis, more than 7 years after treatment, patients treated by radiotherapy reported more bowel symptoms with impact on daily activities, and a trend for more urinary symptoms compared with those treated with vaginal brachytherapy [19].

Menopausal Symptoms and Sexual Disorders

Vasomotor symptoms and sexual disorders are frequently reported by OC survivors, particularly among patients with surgical menopause. In a cohort of 166 OC patients with relapsefree =3 years after the end of treatment, Gernier et al. [20] reported that half of pa-tients had vasomotor symptoms, 2/3 had a decrease in libido, 14% had osteoporosis and 50% osteopenia. Women treated for gynecological malignancies with surgery and adjuvant chemotherapy have significantly lower bone mineral density than age-matched women who have undergone oophorectomy for noncancer indications [21].

In a cohort of 126 young (mean age of 42.4 years) gynecologic cancer survivors (in-cluding OC, EC and cervical carcinomas), 43.7% of sexual dysfunction associated with distress was reported. The main sexual disorders were: loss of sexual interest and arousal disorder [22]. Among 2946 EC and 1165 OC survivors treated between 1997 and 2012, 6.6% had complaint on sexual dysfunction 1-5 years after the end of cancer primary treatment. Compared with healthy women, OC and EC survivors had  higher risks of overall sexual dysfunction (HR: 2.51, 95% CI: 2.16, 2.93), vaginal dryness (HR: 2.63, 95% CI: 2.21, 3.12), and dyspareunia (HR: 3.27, 95% CI: 2.63, 4.06) [23]. Despite increasing knowledge of sexual impairment after gynecological cancer treatment, this topic remains an unmet medical need. Indeed, in a recent Australian study [24], only 22% of OC survivors had the opportunity to discuss the impact of OC on their sexuality with their healthcare team, while 52% had wished to have a discussion on sexual disorders during primary care and 43% still felt the need to discuss 5 years after OC diagnosis. If clinicians wish to address cancer survivors’ sexual health concerns, in order to improve their QoL, they may need help for understanding the strengths and limitations of sexual health screening tools which are complex and multiple [25]. Educational sessions on sexual health concerns among gynecological cancer survivors are needed to help clinicians feel-ing more comfortable with these issues.

Chronic Pain, Peripheral Neuropathy

Chronic pain is also a major issue in cancer survivorship and can concern around one third of cancer survivors, with an negative impact on their QoL [26]. Cancer treatment related pain is made up of multiple components such as post-surgery pain, CIPN, genito-urinary or bowel pain, arthralgia or musculoskeletal pain. A dedicated management is therefore needed and patients may be referred to a pain clinic for multidisciplinary ap-proaches [27].

Chemotherapy-induced peripheral neuropathy (CIPN) is frequent, particularly in OC and EC patients who received chemotherapy. Long-term negative impact of CIPN on QoL has been observed among OC survivors, even a long time after diagnosis. In a cohort of 129 OC patients treated with chemotherapy, 51% suffered from neuropathy up to 12 years after diagnosis, with a frank impairment of their health-related QoL [28]. Among 165 gy-necologic cancer survivors, 21.8% patients had CIPN of Common Toxicity Criteria for Ad-verse Events grade 1 or higher [29]. In order to address the impact of CIPN symptoms in OC and EC survivor’s QoL, early detection and adapted management of CIPN are crucial. Multimodal strategies are needed in order to reduce CIPN symptoms. For example, physi-cal activity can help to improve psychosocial outcomes among gynecologic cancer survi-vors suffering from severe CIPN [30].

Lymphedema

Lymphedema is a frequent, with a potential prevalence as high as 40% in OC survi-vors [31], but poorly understood side effect of gynecologic cancer treatment. In an EC pop-ulation, a Korean study including 19,027 patients, found that 2493 (13.1%) developed lymphedema [32]. Risk factor for lymphedema were most commonly age and multimodal therapy such as pelvic lymphadenectomy incremented by pelvic radiotherapy [33,34].

Lymphedema is associated with decreased physical functioning and activities of dai-ly living limitations, inducing financial difficulties [34]. Among 900 elderly women diag-nosed with EC, OC or colorectal cancer, with a mean age of 78.5 years and a mean time since cancer diagnosis of 8.75 years, Zhang et al. [35], reported that nearly one-third of el-derly female survivors experienced lymphedema and that it was associated with de-creased physical functioning. These findings suggest that clinicians may need to regularly assess lymphedema among older survivors of cancer and provide effective interventions to reduce lymphedema symptoms.

Geriatric Concerns and Cognition Impairment

With a median age at diagnosis of 65-70 years and an improved prognosis due to medical advances, the number of elderly EC and OC survivors is constantly growing. Management of these patients needs to rely on comprehensive data concerning their long-term health-related QoL and their specific needs. Longterm sexuality and QoL of elderly OC and EC patients has been reported by Mamguem Kamga A et al [36] : EC survivors had more deterioration on their physical QoL compared with OC survivors. For OC survi-vors, only physical functioning was impacted (p = 0.012), while EC survivors QoL was al-tered in multiple areas: physical functioning (p < 0.0001), role emotional (p = 0.018), role physical (p = 0.001), and chronic pain (p = 0.001). Concerning neurotoxicity, it has been demonstrated that CIPN is associated with advanced age. Therefore, elderly OC and EC survivors may require specific attention on this point. Raising awareness and education of patients and professional caregivers for management of long-term CIPN impacts is crucial for survivors QoL [37].

Changes in cognitive function also have been described in OC and EC. In a large pro-spective study, the NRG oncology/ gynecologic oncology group identified a subset of pa-tients had evidence of cognitive decline from baseline during chemotherapy treatment [38]. Cognitive impairment did not seem to be dependent on depression state after treat-ment or to a menopausal condition in a cohort of 73 gynecological cancer survivors, in-cluding 40 EC and 16 OC [39]. Various behavioral interventions have been demonstrated to show improvements in patient’s quality of life and in their perceived cognitive abilities and memory [40]. Management of OC and EC survivors should include prevention strate-gies to avert chemotherapy-related cognitive dysfunction’s effects.

General Long-Term Concerns and Comorbidities

EC patients are particularly affected by comorbidities, mainly cardiovascular morbid-ity which is one of the most frequent cause of death among EC survivors. In comparison with the general population, EC survivors have higher risk for longterm cardiovascular disease, even many years after EC diagnosis [41]. Long time (4-14 years) after cancer diag-nosis, this cohort of 1582 multiple cancer survivors (including 402 gynecologic cancers), reported that cancer survivors were at higher risk of cardiovascular disorders than women from the general population [42]: overweight was observed in 62% of cancer survivors, hypertension for 55.0 %, diabetes in 20.7 % of cases and 18.1 % were inactive. In addition, central adiposity and metabolic syndrome in EC survivors are associated with poor prog-nosis [43]. Nock et al. [44] also compared severe obese EC survivors with BMI = 40 kg/m2, to class I obesity EC survivors and demonstrated that severe obesity was associated with global lower QoL, more sleep disorders and higher depression. In comparison with obese EC patients, EC patients with a normal BMI experienced an improved QoL [45]. Obese EC survivors deterioration of QoL  is manifested by decreased vitality, physical function im-pairment, increased  lymphedema, and elevated fatigue [46].

Global health promotion during survivorship is essential, particularly for patient with risk factors for cardiovascular disease, but this discussion had been addressed by their caregiver for only for one third of cancer survivors [47]: Physical activity and promotion of healthy living is perceived as important for OC and EC patients. Their involvement in physical activity programs can provide improvement in physical functioning and psy-chological well-being [48].

Specificities of Rare Ovarian Tumors

In the aim to assess the specific needs in survivorship for women treated for germ cell and sex cord stromal tumors the GINECO-VIVROVAIRE-Rare tumor study is a two-step investigation to assess i) chronic fatigue and quality of life and ii) long-term side-effects of chemotherapy with a focus on cardiovascular and pulmonary disorders. First results were recently reported at ESMO and ESGO congress 2022 [49]: 6 years after cisplatin-based chemotherapy, similar scores of fatigue and global quality of life were observed between patients and controls. However, patients had more cognitive complaints and more neuropathy, higher risk of premature menopause and reported negative impact on their sexu-al health. Health conditions interfered more in patient’s daily lives than controls. Long-term neurotoxicity and Raynaud’s phenomenon in patients treated with cisplatinbased chemotherapy for malignant ovarian germ cell tumor has been described by Solheim et al [50]: among 83 patients, 28 (57%) women treated with cisplatin-based chemotherapy reported overall neuropathy, compared with 20 (45%) in the nonchemotherapy group (P = .06).

Follow-Up Care in Ovarian and Endometrial Cancers

It is now well known that gynecological cancers longterm survivors still have ongo-ing health concerns and long-term side effects following cancer treatment. The aim of fol-low-up care programs is to address these difficulties more effectively, in coordination with general health providers.

Late side-effects of gynecologic cancer treatment have become an increased aware-ness over the past few years.

Description of these late side-effects on patient’s quality of life have been broadly reported but effective ways to reduce these effects are lacking [51]. Iden-tifying the risk factors for gynecological cancer survivors to have unmet needs many years after primary care is a fundamental issue. Repeated assessments of survivor’s needs dur-ing and after their treatment may contribute to reveal the different issues that should re-ceive further attention by caregivers [52]. These regular assessments could rely on survi-vorship questionnaires such as EORTC QLQ-SURV100 or, in France, the use of INCa sur-vivorship questionnaire [53]. These tools are complete and browse every potential symp-tom experimented by the patient, which is quite interesting for systematic screening as part of clinical trials but, because of the numerous items, their use seem heavy in routine practice. Moreover, these questionnaires are general for all tumors types and they lack of site-specific modules for gynecologic cancers.  The integration of technology, including digital companions to facilitate remote monitoring, and patient’s reported outcome can contribute to accelerate implementation of some programs for survivorship care [54].

A useful tool to identify the needs of cancer survivors is the survivorship planning. For gynecologic cancer patients this planning aims to screen for disease relapse, manage the longterm side effects induced by cancer treatment and coordinate the survivorship care between the different healthcare providers [55]. Scientific societies are now aware of the specific needs of cancer survivors and were able to edit recommendations in order to encourage cancer survivors to receive a survivorship care plan [56]. The survivorship care plan briefly describes cancer diagnosis and treatment, furnishes further detailed infor-mation about longterm side effects and their management, and reminds global health concerns. Survivorship care plans contribute to facilitate the communication between spe-cialized hospital practitioners and primary care providers, and provide key information to the patients on long-term follow-up. The NCCN guidelines [56] provide recommendations for the identification and the management of side effects of cancer and its treatment; to promote healthy lifestyle and preventive care in survivors; and to build a framework for care coordination. The MASCC guidelines of cancer supportive care and survivorship [57] describe cancer symptoms, treatment side effects and disparities in supportive care, they provide detailed recommendations for supportive care management during and after can-cer treatments. Recently, ESMO expert consensus statements on cancer survivorship re-minded the different components of survivorship care [58]: physical and psychological side effects of cancer, social impact of cancer, surveillance for cancer relapse and global health promotion. These different guidelines are the cornerstone for survivorship care and provide help for physicians in charge of these patients, but they are not specific for gynecological cancers.

The recommendations for long-term follow-up for survivors from gynecologic cancer have been defined in the GCIG-Consensus guideline which proposes a gynecologic long term survivorship plan [59]. This plan describes the long-term side effects, sequelae after gynecologic cancer and proposes and health maintenance.

Providing comprehensive and coordinated management for gynecological cancer survivors is a pending issue. Known survivorship care models need a high level of com-munication and coordination between oncologists, primary care providers and all the other caregivers involved in survivor’s management and care. In models of survivorship relying on the primary care physician, the primary care health professionals collaborate with the cancer hospital specialists to achieve optimal care of cancer survivors. The limita-tions of a such model are the means available for primary care physicians to get fully in-volved in survivorship care. Another option, broadly used in many countries, are the sur-vivorship clinics. These clinics aim to provide comprehensive survivorship care in one lo-cation where all the health caregivers collaborate to deliver specialized and high-quality care. These clinics are a very interesting model of survivorship care, but their establish-ment may seem difficult to organize in some regions where health care provider’s scarcity is a current issue.

Another existing model relies on specialized nurses who will, under the cancer specialists and primary care physician’s responsibility, assume the global survivorship care. These models of survivorship care are complementary and their optimization is needed to have a better coordination between the different caregivers. For example, in a nurse-led gyne-cology oncology clinic, an audit found that EC patients treated with radiation had to come to many several  appointments in order to access the different care offers [60]. This audit generated a working group of clinic health care professionnals in order optimize survivor-ship care pathways where patients could consult different professionals at one appointment, and evaluate if it could help the move forward in life after treatment. Halfway be-tween survivorship clinics and primary care physician’s models, there is a room for an-other model which may be the daycare hospitalization. Based on our previous experience in OC survivorship [4,20,49], we aim to design a clinical trial for survivorship care in OC and EC, which could be ultimately extended to cervical carcinomas. This study (NCT05731661) will be a randomized multicentric trial comparing two pathways of sur-vivorship care: patients with OC or EC, at the end of initial treatments, will be evaluated on their specific needs induced by treatments complications with dedicated screening tools developed by an InCa working group [53]. Then, patients will be randomized be-tween (a) an experimental arm where patients will be evaluated by a supportive care team during a daycare hospitalization, and their personalized follow-up care plan will be coor-dinated by a specialized nurse to ensure its application by all caregivers and primary care physicians; (b) an standard arm where patients will receive a personalized survivorship plan only. At 6 and 12 months after inclusion, patients will be re-evaluated on their differ-ent needs in supportive care to investigate their adherence to the survivorship program.

A priority in survivorship care is to achieve coordinated pathways, which can be fa-cilitated by scientific guidelines, personalized health survivorship coordinated passports and education of patients and caregivers.

As previously underlined, a better identification and management of the sides effects and sequelae can contribute to enhance quality of life of gynecological cancer survivors. Another way to limit long-term toxicities and sequelae is to prevent them using de-escalation methods during the primary treatment. Minimally invasive surgery based on laparoscopy for surgical staging of OC , or sentinel node biopsy for surgical maping in EC are options to reduce surgical morbidity [61,62]. Recent advances on molecular and ge-nomic profiling in EC contributed to identify several prognostic subtypes [63]. Of note, the POLE mutated subtype has very favorable prognosis and may be eligible for deescalation of adjuvant therapies. Tailoring adjuvant strategies for early stage EC, based on genomic and molecular profiling, is a challenge to take up in order to refine the selection of patients eligible for multimodal treatments [64,65].

To conclude, OC and EC survivors experience long-term disorders that have a great impact on their QoL and general wellbeing. To treat and ameliorate the late side-effects such as fatigue, genito-urinary and bowel disorders, sexual dysfunction, CIPN, lymphedema, chronic pain, cognition impairment or psychological disorders must be a priority of survivorship care. Survivorship care needs to be delivered by structured care models integrating primary care and oncology services, with the help of tools to facilitate implementation of coordinated care. Survivorship educational programs for health care teams and patients are needed to improve the quality of survivorship care.

Author Contributions:

Data Curation: Coraline Dubot Poitelon; Francois Gernier

Writing-original draft preparation: Coraline Dubot Poitelon

Writing-review and editing: Coraline Dubot Poitelon; Francois Gernier ; Florence Joly

Visualization: , Coraline Dubot Poitelon; Francois Gernier ; Florence Joly

Supervision: Francois Gernier ; Florence Joly

All authors have read and agreed to the published version of the manuscript.”

Funding:  This research received no external funding

Conflicts of Interest: “The authors declare no conflict of interest.”

References

1. Bony CA, Zoe U, Laurent R, Nicholas V, Valerie GA, et al (2017) French network of Cancer registries (FRANCIM). European Journal of Cancer Prevention 26:p 461-468.
2. Rapport INCa :La vie cinq ans après un diagnostic de cancer (2018).
3. Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, et al. (2019) Life after the Diagnosis and Treatment of Ovarian Cancer - An International Survey of Symptoms and Concerns in Ovarian Cancer Survivors Gynecol Oncol 155:126-134.
4. Joly F, Lecheheb AD, Kalbacher E, Heutte N, Clarisse B, et al. (2019) Long-Term Fatigue and Quality of Life among Epithelial Ovarian Cancer Survivors: A GINECO Case/Control VIVROVAIRE I Study Ann Oncol 30:845-852.
5. Boer SM,  Powell ME, Mileshkin L, Katsaros D, Bessette P, et al . (2018) Adjuvant Chemoradiotherapy versus Radiotherapy Alone for Women with High-Risk Endometrial Cancer (PORTEC-3): Final Results of an International, Open-Label, Multicentre, Randomised, Phase 3 Trial Lancet Oncol 19:295-309.
6. Post CCB, Boer SMD, Powell ME, Mileshkin L, Katsaros D, et al .(2020) Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. Int J Radiat Oncol Biol Phys 109:975-986.
7. Zandbergen N, Rooij BHD, Vos MC, Pijnenborg JMA, Boll D, et al . (2019) Changes in Health-Related Quality of Life among Gynecologic Cancer Survivors du-ring the Two Years after Initial Treatment: A Longitudinal Analysis Acta Oncol 58:790-800.
8. Poort H, Rooij BHD, jime Uno H, Weng S, Ezendam NPM, et al . (2020) Patterns and Predictors of Cancer-Related Fatigue in Ovarian and Endometrial Cancers: 1-Year Longitudinal Study Cancer 126:35263533.
9. Yu HC, Wang TJ, Chang CL, Liang SY, Wu SF, et al. (2020) Healthy Life Styles, Sleep and Fatigue in Endometrial Cancer Survivors: A Cross-Sectional Stu-dy J Clin Nurs 29:1372-1380.
10. Palagini L, Miniati M, Massa L, Folesani F, Marazziti D, et al . (2022) Insomnia and Circadian Sleep Disorders in Ovarian Cancer: Evaluation and Management of Underestimated Modifiable Factors Potentially Contributing to Morbidity. J Sleep Res 31:e13510.
11. Fox RS, Gaumond JS, Zee PC, Kaiser K, Tanner EJ, et al. (2022) Optimizing a Behavioral Sleep Intervention for Gynecologic Cancer Survivors: Study Design and Protocol Front Neurosci 16:818718.
12. Seland M, Skrede K, Lindemann K, Skaali T, Blomhoff R, et al. (2022) Distress, Problems and Unmet Rehabilitation Needs after Treatment for Gynecological Can-cer Acta Obstet Gynecol Scand 101:313-322.
13. Horsboel TA, Kjaer SK, Johansen C, Suppli NP, Ammitzbøll G, et al. (2019) Increased Risk for Depression Persists for Years among Women Treated for Gy-necological Cancers - a Register-Based Cohort Study with up to 19 years of Follow-Up Gynecol Oncol 153:625-632.
14. Klapheke AK, Keegan THM, Ruskin R, Cress RD (2020) Depressive Symptoms and Health-Related Quality of Life in Older Women with Gyneco-logic Cancers.J Geriatr Oncol 11:820-827.
15. Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, et al. (2018) LongTerm, Adverse Genitourinary Outcomes among Endometrial Cancer Survivors in a Large, Population-Based Cohort Study. Gynecol Oncol 148:499-506.
16. Segal S, John G, Sammel M, Andy UU, Chu C, et al. (2017) Urinary Incontinence and Other Pelvic Floor Disorders after Radiation Therapy in Endometrial Cancer Survivors. Volume 105 83-88
17. Steineck G, Skokic V, Sjöberg F, Bull C, Alevronta E, et al. (2017) Identifying Radiation-Induced Survivorship Syndromes Affecting Bowel Health in a Co-hort of Gynecological Cancer Survivors PLoS One 12:e0171461.
18. Nout RA, Smit VTHBM, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, et al. (2010) Vaginal Brachytherapy versus Pelvic External Beam Radiotherapy for Patients with En-dometrial Cancer of HighIntermediate Risk (PORTEC-2): An Open-Label, Non-Inferiority, Randomised Trial Lancet 375:816-23.
19. Boer SMD, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. (2015) Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. Int J Radiat Oncol Biol Phys 93:797-809.
20. Gernier F, Gompel A,  Rousset-Jablonski C, Kalbacher E, Floquet A, et al. (2021) Menopausal Symptoms in Epithelial Ovarian Cancer Survivors: A GINECO VIVROVAIRE2 Stu-dy. Gynecol Oncol 163:598604.
21. Stavraka C, Maclaran K, Gabra H, Agarwal R, Ghaem‐Maghami S, et al. (2013) A Study to Evaluate the Cause of Bone Demineralization in Gynecological Cancer Survi-vors .The Oncologist Volume 18:423– 429.
22. Lin H, Fu HC, Wu CH, Tsai YJ, Chou YJ, et al. (2022) Evaluation of sexual dysfunction in gynecologic cancer survivors using DSM-5 diagnostic crite-ria.BMC Womens Health 22:1.
23. Chang CP, Wilson CM, Rowe K, Snyder J, Dodson M, et al. (2022) Sexual Dysfunction among Gynecologic Cancer Survivors in a Population-Based Cohort Study Support Care Cancer 31:51.
24. Stafford L, Russell H, Knoetze E, Wilson V, Little R (2022) Sexual Functioning after Ovarian Cancer: Are Women Receiving the Information and Sup-port They Need? Support Care Cancer 30:45834586.
25. Tounkel I, Nalubola S, Schulz A, Lakhi N (2022) Sexual Health Screening for Gynecologic and Breast Cancer Survivors: A Review and Criti-cal Analysis of Validated Screening Tools.Sex Med 10:100498.
26. Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, et al. (2012) Reducing the Toxicity of Cancer Therapy: Recognizing Needs, Taking Action.Nat Rev Clin Oncol 9:471-8.
27. Hacker KE, Reynolds RK, Uppal S (2018) Ongoing Strategies and Updates on Pain Management in Gynecologic Oncology Patients. Gynecol Oncol 149:410-419.
28. Ezendam NPM, Pijlman B, Bhugwandass C, Pruijt JFM, Mols F, et al. (2014) Chemotherapy-Induced Peripheral Neuropathy and Its Impact on Health-Related Quality of Life among Ovarian Cancer Survivors: Results from the Population-Based PROFILES Registry.Gynecol Oncol 135:510-7.
29. Matsuoka H, Nakamura K, Matsubara Y, Ida N, Saijo M, et al. (2018) The Influence of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life of Gynecologic Cancer Survivors.Int J Gynecol Cancer 28:1394-1402.
30. Thomaier L, Jewett P, Brown K, otlieb R, Teoh D, et al. (2020) The Associations between Physical Activity, Neuropathy Symptoms and Health-Related Quality of Life among Gynecologic Cancer Survivors. Gynecol Oncol 158:361-365.
31. Iyer NS, Cartmel B, Friedman L, Li F, Zhou Y, et al. (2018) Lymphedema in Ovarian Cancer Survivors: Assessing Diagnostic Methods and the Effects of Physical Activity. Cancer 124:1929-1937.
32. Lee SJ, Myong JP, Lee YH, Cho EJ, Lee SJ, et al. (2021) Lymphedema in Endometrial Cancer Survivor: A Nationwide Cohort Study J Clin Med 10:4647.
33. Yoshihara M, Shimono R, Satoko Tsuru S, Kitamura K, Sakuda H, et al. (2020) Risk Factors for Late-Onset Lower Limb Lymphedema after Gynecological Cancer Treatment: A Multi-Institutional Retrospective Study Eur J Surg Oncol 46:1334-1338.
34. SKim SI, Lim MC, Lee JS, Lee Y, Park KB, et al. (2015) Impact of Lower Limb Lymphedema on Quality of Life in Gynecologic Cancer Survivors after Pelvic Lymph Node Dissection Eur J Obstet Gynecol Reprod Biol 192:31-6.
35. Zhang X, McLaughlin EM, Krok-Schoen JL, Naughton M, Bernardo BM, et al. (2022) « Association of Lower Extremity Lymphedema With Physical Functioning and Activities of Daily Living Among Older Survivors of Colorectal, Endometrial, and Ovarian Cancer. JAMA Netw Open 5:e221671.
36. Kamga AM, Bengrine-Lefevre L, Quipourt V, Favier L, Darut-Jouve A, et al. (2021) Long-Term Quality of Life and Sexual Function of Elderly People with En-dometrial or Ovarian Cancer Health Qual Life Outcomes 19:56.
37. Hailey W, Bulls HW, Hoogland AI, Kennedy B, James BW, et al.(2019) A Longitudinal Examination of Associations between Age and Chemotherapy-Induced Peripheral Neuropathy in Patients with Gynecologic Cancer. Gynecol Oncol 152:310–315..
38. Hess LM, Huang HQ, Hanlon AL, Robinson WA, Johnson R, et al. (2015) Cognitive Function during and Six Months Following Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer: An NRG Oncology/Gynecologic Oncology Group Study Gynecol Oncol 139:541-5.
39. Rosa ND, Corte LD, Giannattasio A, Giampaolino F, Carlo CD, et al. (2021) Cancer-Related Cognitive Impairment (CRCI), Depression and Quality of Life in Gy-necological Cancer Patients: A Prospective Study Arch Gynecol Obstet 303:1581-1588.
40. Pearre DC, Bota DA (2018) Chemotherapy-Related Cognitive Dysfunction and Effects on Quality of Life in Gynecologic Cancer Patients.Expert Rev Qual Life Cancer Care 3:19-26.
41. Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, et al. (2017) Long-Term Cardiovascular Outcomes Among Endometrial Cancer Survivors in a Large, Po-pulation-Based Cohort Study J Natl Cancer Inst 110:1342-1351.
42. Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, et al. (2013) Cardiovascular Risk Factors among Long-Term Survivors of Breast, Prostate, Colorec-tal, and Gynecologic Cancers: A Gap in Survivorship Care? J Cancer Surviv 7:253-61.
43. Kokts-Porietis RL, McNeil J, Nelson G, Courneya KS, Cook LS, et al. (2020) Prospective Cohort Study of Metabolic Syndrome and Endometrial Cancer Survi-val. Gynecol Oncol 158:727-733..
44. Nock NL, Dimitropoulos A, Zanotti KM, Waggoner S, Nagel C, et al. (2020) Sleep, Quality of Life, and Depression in Endometrial Cancer Survivors with Obesity See-king Weight Loss Support Care Cancer 28:2311-2319.
45. Karabuga H, Gultekin M, Tulunay G, Yuce K, Ayhan A, et al. (2015) Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adju-vant Radiotherapy. Int J Gynecol Cancer 25:152633.
46. Oldenburg CS, Boll D, Nicolaije KAH, Vos MC, Pijnenborg JMA, et al. (2013) The Relationship of Body Mass Index with Quality of Life among Endometrial Can-cer Survivors: A Study from the PopulationBased PROFILES Registry. Gynecol Oncol 129:216-21.
47. Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, et al. (2013) Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv 7:253-61.
48. Donnelly CM, Lowe-Strong A, Rankin JP, Campbell A, Blaney JM, et al. (2013) A Focus Group Study Exploring Gynecological Cancer Survivors’ Experiences and Per-ceptions of Participating in a RCT Testing the Efficacy of a Home-Based Physical Activity Intervention. Support Care Cancer 21:1697-708.
49. Lobbedez FJ, Ray-Coquard IL, Arbogast SL, Grellard JM (2022) Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study. Annals of Oncology 33:S792-S793.
50. Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, et al. (2019) Long-Term Neurotoxicity and Raynaud’s Phenomenon in Patients Treated with Cisplatin-Based Chemotherapy for Malignant Ovarian Germ Cell Tumor. Acta Obstet Gynecol Scand 98:240-249.
51. Stephen A, Gruenigen VEV (2013) Management of the Late Effects of Treatments for Gynecological Cancer Curr Opin Oncol 25:566-70.
52. Rowlands IJ, Janda M, McKinnon L, Webb PM, Beesley VL, et al. (2015) Prevalence, Predictors, and Correlates of Supportive Care Needs among Women 3-5 Years after a Diagnosis of Endometrial Cancer Support Care Cancer 23:1205-14.
53. Reférentiel Organisationnel national. Soins oncologiques de support des patients adultes atteints de cancer (2021)
54. Maio MD, Basch E, Denis F, Fallowfield LJ, Ganz PA, et al. (2022) The role of patient-reported outcome measures in the continuum of cancer clini-cal care: ESMO Clinical Practice Guideline. Ann Oncol 33:878892.
55. Ritu Salani (2013) Survivorship Planning in Gynecologic Cancer Patients. VOLUME 130:P389-397.
56. Sanft T, Day A, Peterson L, Rodriguez MA, Shannon Ansbaugh S, et al. (2022) NCCN Guidelines Insights: Survivorship, Version 1.2022. J Natl Compr Canc Netw 20:1080-1090.
57. The MASCC Textbook of Cancer Supportive Care and Survivorship (2018)
58. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, et al. (2022) ESMO Expert Consensus Statements on Cancer Survivorship: Promoting High-Quality Survi-vorship Care and Research in Europe Ann Oncol 33:1119-1133.
59. Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, et al. (2022) GCIGConsensus Guideline for Long-Term Survi-vorship in Gynecologic Cancer: A Position Paper from the Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Committee, Cancer Treatment Reviews 107: 102396.
60. Elliot E, (2013) Supporting Patients Following Pelvic Radiotherapy for Endometrial Cancer. Br J Nurs 22:S24, S26-30.
61. Bogani G, Borghi C, Maggiore ULR, Ditto A, Signorelli M, et al. (2017) Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol 24:552-562.
62. Donato VD, Giannini A, Bogani G (2023) Recent Advances in Endometrial Cancer Management. J Clin Med 12:2241.
63. Alexa M, Hasenburg A, Battista MJ (2021) The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers (Basel) 13:1478.
64. D’Augè JG, Cuccu I, Santangelo G, Muzii L, Giannini A, et al (2023) Novel Insights into Molecular Mechanisms of Endometrial Diseases. Biomolecules 13:499.
65. Cuccu I, Oria OD, Sgamba L, Angelis ED, Augè TGD, et al (2023) Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives. Healthcare (Basel) 11: 571.